Gritstone bio Stock - Analyst coverage and pipeline backdrop on a quiet news day
17.06.2026 - 22:20:41 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:19 UTC. Details in the imprint.
Gritstone bio (US3987021022) is moving through the week without new filings or press releases. With no fresh catalyst from management, attention stays on the balance sheet, analyst coverage and the company’s clinical pipeline on the Nasdaq Global Select Market.
All news and background on Gritstone bio stock
Key figures, filings and previous headlines on Gritstone bio stock are bundled in the ad-hoc-news topic hub and on the company’s investor-relations pages.
What recent filings show
Gritstone bio last reported quarterly figures for the first quarter of 2024 on 05/09/2024. According to the company, revenue was $5.5 million, while the net loss widened to $37.6 million on higher research and development expenses. IR release dated 05/09/2024
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $103 million as of 03/31/2024, which management said would fund operations into early 2025. Latest 10-Q filing
Analyst views and consensus
Analyst coverage on Gritstone bio is limited but active. TipRanks summarizes three recent analyst ratings as all "Buy" with a consensus 12-month price target of $4.33 per share, implying significant upside from current levels as of mid-June 2024. Analyst consensus overview
MarketScreener lists a similar consensus profile, with a mix of buy recommendations and speculative risk flags typical for early-clinical biotech stocks focused on oncology and infectious disease. The small analyst universe underlines the stock’s high-risk, high-uncertainty profile.
The product pipeline behind the stock
Gritstone bio develops personalized cancer immunotherapies and infectious-disease vaccines based on its antigen discovery and self-amplifying mRNA platform. Key programs include the GRANITE neoantigen-based candidate in solid tumors and CORAL, a second-generation COVID-19 vaccine program supported by public-sector partners.
Where the stock trades today
Gritstone bio shares (US3987021022) trade on Nasdaq at around $1.00 as of 06/17/2026, 20:10 UTC.
Key facts on Gritstone bio stock
- Company: Gritstone bio Inc.
- ISIN: US3987021022
- WKN: A2N9GC
- Ticker: GRTS
- Venue: Nasdaq
- Price (as of 06/17/2026, 20:10 UTC): 1.00 USD
- Market cap: 150,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: none of the major headline indices such as S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
